Houston, TX, (October 21, 2004) Cytogenix, Inc. (CYGX: OTC: BB)
CytoGenix, Inc. (CYGX: OTC: BB) announces that it has entered into an agreement with the Section of Pediatric Infectious Diseases of Baylor College of Medicine, for mice and cell studies using the company's new antimicrobial agent against a highly dangerous strain of Staphylococcus aureus bacteria.
The Centers for Disease Control and Prevention (CDC), report, "Strains of methicillin-resistant Staphylococcus aureus (MRSA), which had been largely confined to hospitals and long-term care facilities, are emerging in the community. The changing epidemiology of MRSA bears striking similarity to the emergence of penicillinase-mediated resistance in S. aureus decades ago. Even though the origin (hospital or the community) of the emerging MRSA strains is not known, the prevalence of these strains in the community seems likely to increase substantially."
Dr. Sheldon Kaplan, professor of pediatrics at Baylor and chief of service at Texas Children's Hospital Infectious Diseases Center, states, "We are seeing a significant increase in the number of children with community-acquired MRSA infection. A very resistant bug is infecting children in this region of the country. For this reason, we are interested in the results of these experiments with the CytoGenix compound."
Dr. Edward Mason, professor, and Dr. Jesus Vallejo, assistant professor, both in the department of pediatrics infectious diseases section at Baylor, will conduct studies to determine the effect of this novel compound on this strain of MRSA.
"Our antimicrobial product certainly addresses an important medical need, and we welcome the opportunity to collaborate with leading clinicians and scientific investigators to demonstrate its activity against difficult targets," states, Dr. Malcolm Skolnick, CytoGenix, Chairman and CEO.
CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including an antimicrobial compound and, anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a US patent for its core DNA expression technology and has over 40 international or US pending patent applications.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: Communications Director — Juan Ferreira, (407) 774-9949
